Biolinq raises $100M for intradermal glucose sensor for type 2

Biolinq raises $100m to support US launch of intradermal glucose sensor

Biolinq has secured $100m in Series C funds to support the regulatory approval process in the US to launch its intradermal glucose sensor.The post Biolinq raises $100m to support US launch of intradermal glucose sensor appeared first on Medical Device Network.

Biolinq raises $100M for intradermal glucose sensor for type 2

Biolinq, a health technology company developing precision multi-analyte wearable biosensors for metabolic health, announced it secured $100 million in Series C funding.  Alpha Wave Ventures led the round with participation from existing investors AXA IM Alts, M Ventures, LifeSci Venture Partners, RiverVest Venture Partners, Hikma Ventures, Taisho Pharmaceutical, Features Capital and Aphelion Capital. WHAT IT DOES Biolinq offers a wearable patch …

Biolinq closes $100M Series C funding round for biosensor platform

Biolinq’s glucose sensor patch is worn on the upper forearm and provides real-time feedback with a color-changing indicator light. [Photo courtesy of Biolinq]Biolinq said today it has closed a $100 million Series C funding round to advance its biosensor platform. “This financing will bolster Biolinq’s commercial readiness efforts while we pursue regulatory approval for the first intradermal glucose sensor that incorporates activity and sleep inf…

Biolinq Raises $100M to Expand Biowearable Platform for Metabolic Health

What You Should Know:  – Biolinq, a healthcare technology company focused on developing precision multi-analyte biosensors to improve metabolic health raises $100M in Series C financing round led by Alpha Wave Ventures, with participation from several existing investors, including RiverVest Venture Partners, AXA IM Alts, LifeSci Venture Partners, M Ventures, Hikma Ventures, Aphelion Capital, Taisho Pharmaceutical, and Features Capital. – The com…